Normal pancreastatin-like and increased post-glucose insulin levels in young offspring of insulin-resistant non-obese essential hypertensive patients

Journal of Endocrinology

Volumn 153, Issue 2, 1997, Pages 313-318

  Sanchez Margalet V ^a,b   Ramos, E ^a   Mateo, J ^a   Olivan J ^a   Perez Cano R ^a   Goberna, R ^a  

^a UNIVERSITY OF SEVILLE   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ESSENTIAL HYPERTENSION; FEMALE; HEREDITY; HUMAN; INSULIN RESISTANCE; MALE; PRIORITY JOURNAL;

EID: 1842297606     PISSN: 00220795     EISSN: None     Source Type: Journal    
DOI: 10.1677/joe.0.1530313     Document Type: Article

References (39)

1. Daly PA & Landsberg L 1991 Hypertension in obesity and NIDDM. Diabetes Care 14 240-248.
2. Deibert DC & DeFronzo RA 1980 Epinephrine-induced insulin resistance in man. Journal of Clinical Investigation 65 717-721.
3. Dimsdale JE, O'Connor DT, Ziegler M & Mills P 1992 Chromogranin A correlates with norepinephrine release rate. Life Sciences 51 519-525.
4. Doberne L, Greenfield MS, Schulz B & Reaven GM 1981 Enhanced glucose utilization during prolonged glucose clamp studies. Diabetes 30 829-835.
5. Efendic S, Tatemoto K, Mutt V, Quan C, Chang D & Ostenson C-G 1987 Pancreastatin and islet hormone release. Proceedings of the National Academy of Sciences of the USA 84 7257-7260.
6. Esler M, Hasking GJ, Willet IR, Leonard PW, Jennings GL 1985 Noradrenaline release and sympathetic nervous system activity. Journal of Hypertension 3 117-129.
7. Ferranini E, Buzzigoli G, Bonadona R, Giorico MA, Oleggini M, Graziadei L & Bevilacqua S 1987 Insulin resistance in essential hypertension. New England Journal of Medicine 317 350-357.
8. Ferrari P, Weidmann P, Shaw S, Giachino D, Riesen W, Allemann Y & Heynen G 1991 Altered insulin sensitivity, hyperinsulinemia, and dyslipidemia in individuals with a hypertensive parent. American Journal of Medicine 91 589-596.
9. Haffner S, Valdez R, Hazuda H, Mitchell B, Morales P & Stern MP 1992 Prospective analysis of the insulin-resistance syndrome. Diabetes 41 715-722.
10. Havel RJ, Eder HA & Bragdon JH 1985 The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. Journal of Clinical Investigation 34 1345-1352.
11. Iancangelo AL, Fischer-Colbrie R, Koller KJ, Browstein MJ & Eiden LE 1988 The sequence of porcine chromogranin A messenger RNA demonstrates chromogranin A can serve as the precursor for the biologically active hormone, pancreastatin. Endocrinology 155 2339-2341.
12. Julius S 1991 Autonomic nervous dysfunction in essential hypertension. Diabetes Care 14 249-259.
13. Kjeldsen SE, Flaaten B, Eide I, Helgeland I & Leren P 1982 Evidence of increased peripheral catecholamine release in patients with long-standing, untreated essential hypertension. Scandinavian Journal of Clinical and Laboratory Investigation 42 217-223.
14. Kuroda M, Honnor RC, Cushman SW, Londos C & Simpson IA 1987 Regulation of insulin-stimulated glucose transport in the isolated rat adipocyte. Journal of Biological Chemistry 262 245-253.
15. Lager I, Atwall S, Eriksson BM, von Schenk C & Simpson IA 1986 Studies on the insulin-antagonistic effect of catecholamines in normal man. Diabetologia 29 409-416.
16. Pollare T, Lithell H & Berne C 1990 Insulin resistance is a characteristic feature of primary hypertension independent of obesity. Metabolism 39 167-174.
17. Reaven GM 1988 Role of insulin resistance in human disease. Diabetes 37 1595-1607.
18. Reaven GM, Lithell & Landsberg L 1996 Hypertension and associated metabolic abnormalities - the role of insulin resistance and the sympathoadrenal system. New England Journal of Medicine 334 374-381.
19. Sánchez V, Calvo JR & Goberna R 1990 Glycogenolytic effect of pancreastadn in the rat. Bioscience Reports 10 87-91.
20. 2+-dependent mechanism. Biochemical Journal 284 659-662.
21. Sánchez-Margalet V & Goberna R 1994a Pancreastatin inhibits insulin stimulated glycogen synthesis but not glycolysis in rat hepatocytes. Regulatory Peptides 51 215-220.
22. Sánchez-Margalet V & Goberna R 1994b Pancreastatin activates pertussis toxin-sensitive guanylate cyclase and pertussis toxin-insensitive phospholipase C in rat liver membranes. Journal of Cell Biochemistry 55 173-181.
23. Sánchez-Margalet, Calvo JR, Lucas M & Goberna R 1992 Glycogenolytic and hyperglycemic effect of 33-49 C-terminal fragment of pancreastatin in the rat in vivo. Hormones and Metabolism Research 24 455-457.
24. 2+ in rat hepatocytes involving both pertussis-toxin-sensitive and insensitive mechanisms. Biochemical Journal 294 439-442.
25. Sánchez-Margalet V, Valle M & Goberna R 1994a Receptors for pancreastatin in rat liver membranes: molecular characterization by covalent cross-linking. Molecular Pharmacology 46 24-29.
26. Sánchez-Margalet V, Lucas M & Goberna R 1994b Pancreastatin activates protein kinase C by stimulating the formation of 1,2-diacylglycerol in rat hepatocytes. Biochemical Journal 303 51-54.
27. Sánchez-Margalet V, Valle M, Lobon JA, Escobar-Jimenez F, Perez-Cano R & Goberna R 1995a Plasma pancreastatin-like immunoreactivity correlates with plasma norepinephrine levels in essential hypertension. Neuropeptides 29 22-27.
28. Sánchez-Margalet V, Valle M, Lobón JA, Maldonado A, Escobar-Jimenez F, Oliván J, Pérez-Cano R & Goberna R 1995b Increased plasma pancreastatin-like immunoreactivity levels in non-obese patients with essential hypertension. Journal of Hypertension 13 251-258.
29. Sánchez-Margalet V, Lucas M & Goberna R 1996a Pancreastatin: further evidence for its consideration as a regulatory peptide. Journal of Molecular Endocrinology 16 1-8.
30. Sánchez-Margalet V, Lucas M & Goberna R 1996b Pancreastatin action in the liver: dual coupling to different G proteins. Cell Signal 8 9-12.
31. Schmidt WE, Siegel EG, Lamberts R, Gallwitz B & Creutzfeldt W 1988 Pancreastatin: molecular and immunocytochemical characterization of a novel peptide in porcine and human tissues. Endocrinology 123 1395-1404.
32. Shen DC, Sheih SM, Fuh M, Chen Y-DI & Reaven GM 1988 Resistance to insulin-stimulated glucose uptake in patients with hypertension. Journal of Clinical Endocrinology and Metabolism 66 580-583.
33. Simon JP, Bader MF & Aunis D 1989 Proteolytic processing of CGA in cultured chromaffin cells. Biochimica et Biophysica Acta 1051 123-130.
34. Skarfors ET, Lithell HO & Selinus I 1991 Risk factors for the development of hypertension: a 10-year longitudinal study in middle-aged men. Journal of Hypertension 9 217-223.
35. Syversen U, Jacosen MB, O'Connor DT, Ronning K & Waldum HL 1994 Immunoassays for measurement of chromogranin A and pancreastatin-like immunoreactivity in humans: Correspondence in patients with neuroendocrine neoplasia. Neuropeptides 26 201-206.
36. Tatemoto K, Efendic S, Mutt V, Makk G, Feistner GJ & Barchas 1986 Pancreastatin, a novel pancreatic peptide that inhibits insulin secretion. Nature 324 476-478.
37. Watkinson A, Jonsson AC, Davison M, Young J, Lee CM, Moore S & Dockray GJ 1991 Heterogeneity of chromogranin A-derived peptides in bovine gut, pancreas and adrenal medulla. Biochemical Journal 276 471-479.
38. Watkinson A, Jonsson AC, Davison M, Young J, Lee CM, Moore S & Dockray GJ 1993 Post-translational processing of chromogranin A: differential distribution of phosphorylated variants of pancreastatin and fragments 248-313 and 297-313 in bovine gut, pancreas and adrenal medulla. Biochemical Journal 295 649-654.
39. Winkler H & Fischer-Colbrie R 1992 The chromogranin-A and chromogranin-B - the first 25 years and future perspectives. Neurosciences 49 497-528.